KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Shares Repurchased (2017 - 2022)

Pfizer (PFE) has disclosed Shares Repurchased for 11 consecutive years, with $2.0 billion as the latest value for Q4 2022.

  • Quarterly Shares Repurchased changed N/A to $2.0 billion in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Oct 2023, down 50.0% year-over-year, with the annual reading at $2.0 billion for FY2022, N/A changed from the prior year.
  • Shares Repurchased for Q4 2022 was $2.0 billion at Pfizer, roughly flat from $2.0 billion in the prior quarter.
  • The five-year high for Shares Repurchased was $8.9 billion in Q1 2019, with the low at $1.1 billion in Q3 2018.
  • Average Shares Repurchased over 3 years is $4.2 billion, with a median of $3.5 billion recorded in 2018.
  • The sharpest move saw Shares Repurchased grew 21.26% in 2018, then soared 46.21% in 2019.
  • Over 3 years, Shares Repurchased stood at $5.0 billion in 2018, then soared by 76.24% to $8.9 billion in 2019, then plummeted by 77.44% to $2.0 billion in 2022.
  • According to Business Quant data, Shares Repurchased over the past three periods came in at $2.0 billion, $2.0 billion, and $8.9 billion for Q4 2022, Q2 2022, and Q1 2019 respectively.